Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Short-term Investments (2020 - 2026)

Nautilus Biotechnology has reported Short-term Investments over the past 7 years, most recently at $81.2 million for Q1 2026.

  • Quarterly results put Short-term Investments at $81.2 million for Q1 2026, down 23.04% from a year ago — trailing twelve months through Mar 2026 was $81.2 million (down 23.04% YoY), and the annual figure for FY2025 was $91.0 million, down 10.98%.
  • Short-term Investments reached $81.2 million in Q1 2026 per NAUT's latest filing, down from $91.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $155.6 million in Q1 2024 and bottomed at $69.0 million in Q3 2022.
  • Median Short-term Investments over the past 5 years was $105.6 million (2025), compared with a mean of $107.8 million.
  • The largest annual shift saw Short-term Investments tumbled 56.31% in 2022 before it skyrocketed 120.19% in 2023.
  • Over 5 years, Short-term Investments stood at $69.9 million in 2022, then surged by 120.19% to $154.0 million in 2023, then tumbled by 33.61% to $102.2 million in 2024, then fell by 10.98% to $91.0 million in 2025, then decreased by 10.74% to $81.2 million in 2026.
  • Business Quant data shows Short-term Investments for NAUT at $81.2 million in Q1 2026, $91.0 million in Q4 2025, and $107.6 million in Q3 2025.